Dipòsit Digital de Documents de la UAB 10 registres trobats  La cerca s'ha fet en 0.06 segons. 
1.
11 p, 544.2 KB Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents / Riudavets, Mariona (Universitat Autònoma de Barcelona. Departament de Medicina) ; Mosquera, Joaquin (Complejo Hospitalario Universitario de A Coruña) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Serra, Jorgina (Institut d'Investigació Biomèdica Sant Pau) ; Anguera, Georgia (Institut d'Investigació Biomèdica Sant Pau) ; Gallardo, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Barba, Andrés (Institut d'Investigació Biomèdica Sant Pau) ; del Carpio, Luís (Institut d'Investigació Biomèdica Sant Pau) ; Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Gich, Ignasi (Institut d'Investigació Biomèdica Sant Pau) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. [...]
2020 - 10.3389/fonc.2020.01677
Frontiers in Oncology, Vol. 10 (september 2020)  
2.
10 p, 621.9 KB Obesity and Breast Cancer : a Paradoxical and Controversial Relationship Influenced by Menopausal Status / García-Estévez, Laura (Centro de Investigación Biomédica en Red de Cáncer) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Pérez, Silvia (Breast Cancer Department, MD Anderson Cancer Center) ; Calvo Plaza, Isabel (Breast Cancer Department, MD Anderson Cancer Center) ; Gallegos, Isabel (Breast Cancer Department, MD Anderson Cancer Center) ; Moreno-Bueno, Gema (MD Anderson International Foundation) ; Universitat Autònoma de Barcelona
Breast cancer is the most common tumor in women worldwide, and an increasing public health concern. Knowledge of both protective and negative risk factors is essential for a better understanding of this heterogenous disease. [...]
2021 - 10.3389/fonc.2021.705911
Frontiers in Oncology, Vol. 11 (august 2021)  
3.
0 p, 170.6 KB Commentary : SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China / Di Cosimo, S. (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano) ; Porcu, L. (Istituto di Ricerche Farmacologiche Mario Negri IRCCS) ; Malfettone, Andrea (Medica Scientia Innovation Research (New Jersey, Estats Units d'Amèrica)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Miceli, R. (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano. Department of Applied Research and Technological Development) ; Universitat Autònoma de Barcelona
2020 - 10.3389/fonc.2020.01223
Frontiers in Oncology, Vol. 10 (july 2020) , p. 1223  
4.
9 p, 1.3 MB Towards a Better Understanding of Cohesin Mutations in AML / Cuartero, Sergi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Innes, A.J. (Faculty of Medicine. Centre for Haematology. Imperial College London) ; Merkenschlager, M. (Imperial College London. Institute of Clinical Sciences) ; Universitat Autònoma de Barcelona
Classical driver mutations in acute myeloid leukemia (AML) typically affect regulators of cell proliferation, differentiation, and survival. The selective advantage of increased proliferation, improved survival, and reduced differentiation on leukemia progression is immediately obvious. [...]
2019 - 10.3389/fonc.2019.00867
Frontiers in Oncology, Vol. 9 (september 2019) , p. 867  
5.
14 p, 1.4 MB Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors / Pasculli, B. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ; Barbano, R. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ; Fontana, Andrea (Fondazione IRCCS Casa Sollievo Della Sofferenza) ; Biagini, T. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratory of Bioinformatics Unit) ; Di Viesti, M.P. (Department of Medicine. Scuola Medica Salernitana," University of Salerno) ; Rendina, M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ; Valori, V.M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ; Morritti, M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ; Bravaccini, S. (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Biosciences Laboratory) ; Ravaioli, S. (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Biosciences Laboratory) ; Maiello, Evaristo (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ; Graziano, P. (Fondazione IRCCS Casa Sollievo Della Sofferenza) ; Murgo, R. (Fondazione IRCCS Casa Sollievo Della Sofferenza) ; Copetti, Massimiliano (Fondazione IRCCS Casa Sollievo Della Sofferenza) ; Mazza, T. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratory of Bioinformatics Unit) ; Fazio, V.M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Parrella, P. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ; Universitat Autònoma de Barcelona
miR-155-5p is a well-known oncogenic microRNA, showing frequent overexpression in human malignancies, including breast cancer. Here, we show that high miR-155-5p levels are associated with unfavorable prognostic factors in two independent breast cancer cohorts (CSS cohort, n = 283; and TCGA-BRCA dataset, n = 1,095). [...]
2020 - 10.3389/fonc.2020.01415
Frontiers in Oncology, Vol. 10 (december 2020) , p. 1415  
6.
15 p, 1.5 MB Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NAD+ Dependent Lysine Deacetylases / Wössner, N. (Department of Pharmaceutical and Medicinal Chemistry. Institute of Pharmaceutical Sciences. University of Freiburg) ; Alhalabi, Z. (Department of Medicinal Chemistry. Institute of Pharmacy. University of Halle-Wittenberg) ; González, J. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Swyter, S. (Department of Pharmaceutical and Medicinal Chemistry. Institute of Pharmaceutical Sciences. University of Freiburg) ; Gan, J. (Department of Cell and Chemical Biology. Oncode Institute. Leiden University Medical Center) ; Schmidtkunz, K. (Department of Pharmaceutical and Medicinal Chemistry. Institute of Pharmaceutical Sciences. University of Freiburg) ; Zhang, L. (Department of Protein Crystallography. Institute of Biochemistry. University of Freiburg) ; Vaquero, Alejandro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ovaa, H. (Department of Cell and Chemical Biology. Oncode Institute. Leiden University Medical Center) ; Einsle, O. (Department of Protein Crystallography. Institute of Biochemistry. University of Freiburg) ; Sippl, W. (Department of Medicinal Chemistry. Institute of Pharmacy. University of Halle-Wittenberg) ; Jung, M. (Department of Pharmaceutical and Medicinal Chemistry. Institute of Pharmaceutical Sciences. University of Freiburg) ; Universitat Autònoma de Barcelona
Sirtuin 1 (Sirt1) is a NAD dependent lysine deacetylase associated with the pathogenesis of various diseases including cancer. In many cancer types Sirt1 expression is increased and higher levels have been associated with metastasis and poor prognosis. [...]
2020 - 10.3389/fonc.2020.00657
Frontiers in Oncology, Vol. 10 (30 2020) , p. 657  
7.
1.1 MB Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer / Boloix, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sánchez de Toledo, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In recent decades, biomedical research has focused on understanding the functionality of the human translated genome, which represents a minor part of all genetic information transcribed from the human genome. [...]
2019 - 10.3389/fonc.2019.01173
Frontiers in Oncology, Vol. 9 (november 2019)  
8.
16 p, 2.8 MB PVT1 Long Non-coding RNA in Gastrointestinal Cancer / Martínez-Barriocanal, Águeda (Hospital Universitari Vall d'Hebron) ; Arango, Diego (Hospital Universitari Vall d'Hebron) ; Dopeso, Higinio (Hospital Universitari Vall d'Hebron) ; VHIR Vall d'Hebron Institut de Recerca ; Universitat Autònoma de Barcelona
Whole genome and transcriptome sequencing technologies have led to the identification of many long non-coding RNAs (lncRNAs) and stimulated the research of their role in health and disease. LncRNAs participate in the regulation of critical signaling pathways including cell growth, motility, apoptosis, and differentiation; and their expression has been found dysregulated in human tumors. [...]
2020 - 10.3389/fonc.2020.00038
Frontiers in Oncology, Vol. 10 (january 2020)  
9.
0 p, 1.1 MB FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness : Its Relationship With TGF-β1 and NF-κB Pathways / Besso, M.J. (Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer. Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME)) ; Rosso, M. (Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer. Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME)) ; Lapyckyj, L. (Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer. Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME)) ; Moiola, Cristian Pablo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Matos, M.L. (Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer. Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME)) ; Mercogliano, M.F. (Instituto de Biología y Medicina Experimental (Buenos Aires, Argentina)) ; Schillaci, R. (Instituto de Biología y Medicina Experimental (Buenos Aires, Argentina)) ; Reventós Puigjaner, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Gil-Moreno, Antonio (Hospital Universitari Vall d'Hebron) ; Wernicke, A. (Hospital Italiano de Buenos Aires) ; Orti, R. (Hospital Italiano de Buenos Aires) ; Vazquez-Levin, M.H. (Laboratorio de Estudios de la Interacción Celular en Reproducción y Cáncer. Instituto de Biología y Medicina Experimental (IBYME; CONICET-FIBYME)) ; Universitat Autònoma de Barcelona
Objective: Endometrial cancer (EC) is the second most common gynecological cancer worldwide. Myometrial invasion (MI) is a key event in EC dissemination. This study aimed to evaluate FXYD5/dysadherin (FXYD5/Dys) expression in EC tissue and uterine aspirate (UA) biopsies and to assess molecular/functional changes associated with its expression in cellular models. [...]
2019 - 10.3389/fonc.2019.01306
Frontiers in Oncology, Vol. 9 (june 2019) , p. 1306  
10.
10 p, 637.1 KB Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients : FN14 and GRP94 from Diagnosis to Prophylaxis / Martínez-Aranda, Antonio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hernández, Vanessa (Institut d'Investigació Biomèdica de Bellvitge) ; Moreno, Ferran (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Baixeras, Núria (Hospital Universitari de Bellvitge) ; Cuadras, Daniel (Statistical Service, Sant Joan de Déu Research Foundation) ; Urruticoechea, Ander (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gil-Gil, Miguel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vidal, Noemí (Hospital Universitari de Bellvitge) ; Andreu, Xavier (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Seguí, Miquel A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Ballester Alabau, Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Castella, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sierra, Angels (Universitat de Vic - Universitat Central de Catalunya. Facultat de Medicina) ; Universitat Autònoma de Barcelona
FN14 has been implicated in many intracellular signaling pathways, and GRP94 is a well-known endoplasmic reticulum protein regulated by glucose. Recently, both have been associated with metastasis progression in breast cancer patients. [...]
2017 - 10.3389/fonc.2017.00283
Frontiers in Oncology, Vol. 7 (december 2017)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.